A recent study from the Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; The James Cancer Hospital, The Ohio State University, Columbus, OH, USA shows that Transcription factor foxo1 is a negative regulator of NK cell maturation and function. This study was published in the 10 March 2015 issue of Immunity (the number 1 journal in the field of Immunological research with an impact factor of 19.748) by Prof Yu J, Deng Y, and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Interleukin-based Immune augmentation therapy: IL-1β (Interleukin-1β) promotes NK cell maturation and function via down regulation of its target gene
Significance:
This study suggests, for the first time, a natural product-based NK-cell therapy: IL-1β , by suppressing the expression of its target gene, it may decrease the expression of FOXO1. Thereby, it may promote NK cell maturation and function. Thus, pharmacological formulations encompassing “IL-1β activators” may be used to (1) increase NK cell function; and (2) eradicate large solid tumors.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Interleukin-based Immune augmentation therapy: IL-1β (Interleukin-1β) promotes NK cell maturation and function via down regulation of its target gene, 21/April/2014, 19.48, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
Undisclosed information: How IL-1β decreases Foxo1 expression and increases NK cell function.
